These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10455521)

  • 1. Gender-related differences in vascular smooth muscle cell proliferation: implications for prevention of atherosclerosis.
    Fitzpatrick LA; Ruan M; Anderson J; Moraghan T; Miller V
    Lupus; 1999; 8(5):397-401. PubMed ID: 10455521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential response in cell proliferation to beta estradiol in coronary arterial vascular smooth muscle cells obtained from mature female versus male animals.
    Moraghan T; Antoniucci DM; Grenert JP; Sieck GC; Johnson C; Miller VM; Fitzpatrick LA
    Endocrinology; 1996 Nov; 137(11):5174-7. PubMed ID: 8895395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in the effect of genistein on vascular smooth muscle cells: a possible cardioprotective effect?
    Vincent A; Ruan M; Fitzpatrick LA
    J Gend Specif Med; 2001; 4(1):28-34. PubMed ID: 11324237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-related differences in proliferative responses of vascular smooth muscle cells to endothelin-1.
    Antoniucci D; Miller VM; Sieck GC; Fitzpatrick LA
    Endothelium; 2001; 8(2):137-45. PubMed ID: 11572475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender-related differences in the development of atherosclerosis: studies at the cellular level.
    Fitzpatrick LA
    Clin Exp Pharmacol Physiol; 1996 Mar; 23(3):267-9. PubMed ID: 8934620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effect of estrogen in vascular smooth muscle cells is mediated by Kruppel-like factor-4 and manganese superoxide dismutase.
    Sivritas D; Becher MU; Ebrahimian T; Arfa O; Rapp S; Bohner A; Mueller CF; Umemura T; Wassmann S; Nickenig G; Wassmann K
    Basic Res Cardiol; 2011 Jun; 106(4):563-75. PubMed ID: 21484412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery.
    Vargas R; Wroblewska B; Rego A; Hatch J; Ramwell PW
    Br J Pharmacol; 1993 Jul; 109(3):612-7. PubMed ID: 8358561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-mitogenic activity of 17beta-estradiol in coronary smooth muscle cells correlates with protein binding to its responsive element.
    Ramos KS; Sadhu DN; Meininger CJ; Chilian WM
    In Vitro Cell Dev Biol Anim; 1997; 33(10):738-41. PubMed ID: 9466675
    [No Abstract]   [Full Text] [Related]  

  • 9. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women.
    Losordo DW; Kearney M; Kim EA; Jekanowski J; Isner JM
    Circulation; 1994 Apr; 89(4):1501-10. PubMed ID: 8149515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular protective effects of estrogen.
    Farhat MY; Lavigne MC; Ramwell PW
    FASEB J; 1996 Apr; 10(5):615-24. PubMed ID: 8621060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen regulation of a transforming growth factor-beta inducible early gene that inhibits deoxyribonucleic acid synthesis in human osteoblasts.
    Tau KR; Hefferan TE; Waters KM; Robinson JA; Subramaniam M; Riggs BL; Spelsberg TC
    Endocrinology; 1998 Mar; 139(3):1346-53. PubMed ID: 9492071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells.
    Rizvi MA; Katwa L; Spadone DP; Myers PR
    J Mol Cell Cardiol; 1996 Feb; 28(2):243-52. PubMed ID: 8729057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of iodothyronine deiodinase and roles of thyroid hormones in human coronary artery smooth muscle cells.
    Kasahara T; Tsunekawa K; Seki K; Mori M; Murakami M
    Atherosclerosis; 2006 May; 186(1):207-14. PubMed ID: 16140305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catecholamines block the antimitogenic effect of estradiol on human coronary artery smooth muscle cells.
    Dubey RK; Jackson EK; Gillespie DG; Zacharia LC; Imthurn B
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3922-31. PubMed ID: 15292328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous estrogen deficiency reduces proliferation and enhances apoptosis-related death in vascular smooth muscle cells: insights from the aromatase-knockout mouse.
    Ling S; Dai A; Dilley RJ; Jones M; Simpson E; Komesaroff PA; Sudhir K
    Circulation; 2004 Feb; 109(4):537-43. PubMed ID: 14732746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth.
    García-Ramírez M; Martínez-González J; Juan-Babot JO; Rodríguez C; Badimon L
    Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2398-403. PubMed ID: 16179596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques.
    Bennett MR; Evan GI; Schwartz SM
    J Clin Invest; 1995 May; 95(5):2266-74. PubMed ID: 7738191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells.
    Blaschke F; Bruemmer D; Yin F; Takata Y; Wang W; Fishbein MC; Okura T; Higaki J; Graf K; Fleck E; Hsueh WA; Law RE
    Circulation; 2004 Aug; 110(5):579-87. PubMed ID: 15277326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells.
    del Rio M; Sunkel C; Larcher F; Ortega MP
    Br J Pharmacol; 1997 Apr; 120(7):1360-6. PubMed ID: 9105713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.